Table 2.
Control women | All T2DM women | T2DM women without CHD | T2DM women with CHD | P1 | P2 | Age- adjusted P2 | |
---|---|---|---|---|---|---|---|
n | 55 | 132 | 96 | 36 | |||
Resistin(ng/ml) | 10.31 ± 4.28 | 10.27 ± 4.11 | 9.50 ± 3.33 | 12.43 ± 5.21 | 0.953 | < 0.001 | 0.013 |
hsPCR (mg/L) | 2.97 ± 3.27 | 5.54 ± 6.42 | 5.83 ± 7.34 | 4.90 ± 4.55 | 0.0132 | 0.452 | 0.682 |
IL-6 (pg/ml) | 2.17 ± 2.07 | 2.87 ± 2.07 | 2.72 ± 3.84 | 3.35 ± 2.03 | 0.109 | 0.317 | 0.913 |
sVCAM1 (ng/ml) | 715.07 ± 202.63 | 768.65 ± 313.48 | 707.32 ± 194.80 | 940.11 ± 481.97 | 0.245 | < 0.001 | 0.118 |
tHcy (μmol/L) | 11.47 ± 4.58 | 12.77 ± 5.94 | 11.68 ± 5.01 | 15.92 ± 7.25 | 0.165 | < 0.001 | 0.799 |
Data are n, means ± DS
P1: P value for the comparison between T2DM and control women participating to the study
P 2: P value for the comparison between T2DM women with and without CHD